R&D Trends

Parent Project Muscular Dystrophy funds UCLA project

Friday, March 1, 2013 12:46 PM

Parent Project Muscular Dystrophy (PPMD) will provide $100,000 to Dr. Stanley Nelson of the University of California, Los Angeles, to examine the genomes of 40 boys with Duchenne muscular dystrophy who are either very mildly affected or very severely affected.  The goal is to identify changes in genes other than dystrophin that may affect the course of the disease.

More... »

Medicines Patent Pool collaborates with ViiV Healthcare

Friday, March 1, 2013 12:39 PM

The Medicines Patent Pool (MPP) has launched a collaboration with ViiV Healthcare—a joint venture of GlaxoSmithKline, Pfizer and Shionogi—to facilitate greater availability of critically needed medicines for children living with HIV.

More... »

Roche launches process for accessing clinical trial data

Thursday, February 28, 2013 02:24 PM

Basel, Switzerland-based Roche is expanding access to its clinical trial data for third-party researchers. Roche will work with an independent body of recognized experts to evaluate and approve requests to access anonymized patient-level data.

More... »

MJFF surpasses $50M with Brin Wojcicki Challenge

Thursday, February 28, 2013 08:00 AM

The Michael J. Fox Foundation for Parkinson's Research (MJFF) it has completed and surpassed the $50 million Brin Wojcicki Challenge. Longtime foundation supporters Sergey Brin and Anne Wojcicki have matched more than $53 million in capacity-building gifts received by MJFF from January 1, 2011, to December 31, 2012.

More... »

Jazz, Concert partner to develop deuterium-modified sodium oxybate

Wednesday, February 27, 2013 11:54 AM

Jazz Pharmaceuticals, an Irish specialty biopharmaceutical company focused on unmet medical needs, and Concert Pharmaceuticals, a Lexington, Mass.-based clinical stage biotechnology company, have signed an exclusive license agreement that provides Jazz Pharmaceuticals worldwide rights to develop and commercialize Concert's deuterium-modified sodium oxybate (D-SXB) compounds, including C-10323.   

More... »

LEO Pharma, 4SC Discovery ink exclusive research agreement

Tuesday, February 26, 2013 01:48 PM

LEO Pharma, a global pharmaceutical company specializing in dermatology, has entered into an exclusive research and license agreement with the German biotech company 4SC Discovery with the primary aim of jointly researching, developing and commercializing an oral treatment for inflammatory skin diseases such as psoriasis.

More... »

CDRD Ventures inks new partnership with Pfizer

Tuesday, February 26, 2013 11:29 AM

Pfizer and CDRD Ventures (CVI), the commercialization vehicle of the Center for Drug Research and Development (CDRD), have formed a strategic collaboration designed to provide new resources to advance Canada’s most innovative and therapeutically promising health technologies towards commercialization.

More... »

RWJF awards $1.9M grant to PatientsLikeMe

Monday, February 25, 2013 11:26 AM

PatientsLikeMe, a patient network that improves lives and a real-time research platform that advances medicine, has been awarded a $1.9 million grant from the Robert Wood Johnson Foundation (RWJF) to create the world's first open-participation research platform for the development of patient-centered health outcome measures.

More... »

MJFF launches new funding opportunities for Parkinson's research

Monday, February 25, 2013 09:31 AM

The Michael J. Fox Foundation (MJFF) has launched four new funding programs focused on driving forward research toward transformative treatments and a cure for Parkinson's disease (PD).

More... »

UCB and ConfometRx announce new R&D partnership

Friday, February 22, 2013 12:13 PM

UCB, a Belgium-based biopharmaceutical company, has sealed a research agreement with Santa Clara, Calif.-based ConfometRx to enable the discovery of novel medicines addressing unmet medical needs in neuroscience.

More... »